169 related articles for article (PubMed ID: 38145445)
1. Engineering Human Pancreatic RNase 1 as an Immunotherapeutic Agent for Cancer Therapy Through Computational and Experimental Studies.
Nassiri M; Ghovvati S; Gharouni M; Tahmoorespur M; Bahrami AR; Dehghani H
Protein J; 2024 Apr; 43(2):316-332. PubMed ID: 38145445
[TBL] [Abstract][Full Text] [Related]
2. Tandemization endows bovine pancreatic ribonuclease with cytotoxic activity.
Leich F; Köditz J; Ulbrich-Hofman R; Arnold U
J Mol Biol; 2006 May; 358(5):1305-13. PubMed ID: 16580680
[TBL] [Abstract][Full Text] [Related]
3. Production of human pancreatic ribonuclease in Saccharomyces cerevisiae and Escherichia coli.
Ribó M; delCardayré SB; Raines RT; de Llorens R; Cuchillo CM
Protein Expr Purif; 1996 May; 7(3):253-61. PubMed ID: 8860650
[TBL] [Abstract][Full Text] [Related]
4. Degradation of double-stranded RNA by human pancreatic ribonuclease: crucial role of noncatalytic basic amino acid residues.
Sorrentino S; Naddeo M; Russo A; D'Alessio G
Biochemistry; 2003 Sep; 42(34):10182-90. PubMed ID: 12939146
[TBL] [Abstract][Full Text] [Related]
5. Engineered human angiogenin mutations in the placental ribonuclease inhibitor complex for anticancer therapy: Insights from enhanced sampling simulations.
Cong X; Cremer C; Nachreiner T; Barth S; Carloni P
Protein Sci; 2016 Aug; 25(8):1451-60. PubMed ID: 27110669
[TBL] [Abstract][Full Text] [Related]
6. Role of the N terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity.
Boix E; Wu Y; Vasandani VM; Saxena SK; Ardelt W; Ladner J; Youle RJ
J Mol Biol; 1996 Apr; 257(5):992-1007. PubMed ID: 8632481
[TBL] [Abstract][Full Text] [Related]
7. Cloning and cytotoxicity of a human pancreatic RNase immunofusion.
Zewe M; Rybak SM; Dübel S; Coy JF; Welschof M; Newton DL; Little M
Immunotechnology; 1997 Jun; 3(2):127-36. PubMed ID: 9237097
[TBL] [Abstract][Full Text] [Related]
8. Engineering ribonuclease A: production, purification and characterization of wild-type enzyme and mutants at Gln11.
delCardayré SB; Ribó M; Yokel EM; Quirk DJ; Rutter WJ; Raines RT
Protein Eng; 1995 Mar; 8(3):261-73. PubMed ID: 7479688
[TBL] [Abstract][Full Text] [Related]
9. A novel fully human antitumor immunoRNase resistant to the RNase inhibitor.
Riccio G; D'Avino C; Raines RT; De Lorenzo C
Protein Eng Des Sel; 2013 Mar; 26(3):243-8. PubMed ID: 23232187
[TBL] [Abstract][Full Text] [Related]
10. Production and introduction of a novel immunotoxin based on engineered RNase A for inducing death to Her1-positive cell lines.
Forouharmehr A; Nassiri M; Ghovvati Roudsari S; Javadmanesh A
J Cell Physiol; 2020 May; 235(5):4679-4687. PubMed ID: 31663127
[TBL] [Abstract][Full Text] [Related]
11. Site-specific mutagenesis reveals differences in the structural bases for tight binding of RNase inhibitor to angiogenin and RNase A.
Chen CZ; Shapiro R
Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1761-6. PubMed ID: 9050852
[TBL] [Abstract][Full Text] [Related]
12. Ribonuclease A variants with potent cytotoxic activity.
Leland PA; Schultz LW; Kim BM; Raines RT
Proc Natl Acad Sci U S A; 1998 Sep; 95(18):10407-12. PubMed ID: 9724716
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human pancreatic ribonuclease by the human ribonuclease inhibitor protein.
Johnson RJ; McCoy JG; Bingman CA; Phillips GN; Raines RT
J Mol Biol; 2007 Apr; 368(2):434-49. PubMed ID: 17350650
[TBL] [Abstract][Full Text] [Related]
14. Role of aspartic acid 121 in human pancreatic ribonuclease catalysis.
Gaur D; Batra JK
Mol Cell Biochem; 2005 Jul; 275(1-2):95-101. PubMed ID: 16335788
[TBL] [Abstract][Full Text] [Related]
15. Studies on the interaction of ribonuclease inhibitor with pancreatic ribonuclease involving differential labeling of cysteinyl residues.
Hofsteenge J; Servis C; Stone SR
J Biol Chem; 1991 Dec; 266(35):24198-204. PubMed ID: 1748689
[TBL] [Abstract][Full Text] [Related]
16. Interaction of human pancreatic ribonuclease with human ribonuclease inhibitor. Generation of inhibitor-resistant cytotoxic variants.
Gaur D; Swaminathan S; Batra JK
J Biol Chem; 2001 Jul; 276(27):24978-84. PubMed ID: 11342552
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of RNase A tandem enzymes and their interaction with the cytosolic ribonuclease inhibitor.
Arnold U; Leich F; Neumann P; Lilie H; Ulbrich-Hofmann R
FEBS J; 2011 Jan; 278(2):331-40. PubMed ID: 21134128
[TBL] [Abstract][Full Text] [Related]
18. Fluorescence assay for the binding of ribonuclease A to the ribonuclease inhibitor protein.
Abel RL; Haigis MC; Park C; Raines RT
Anal Biochem; 2002 Jul; 306(1):100-7. PubMed ID: 12069420
[TBL] [Abstract][Full Text] [Related]
19. Disruption of shape-complementarity markers to create cytotoxic variants of ribonuclease A.
Rutkoski TJ; Kurten EL; Mitchell JC; Raines RT
J Mol Biol; 2005 Nov; 354(1):41-54. PubMed ID: 16188273
[TBL] [Abstract][Full Text] [Related]
20. Engineering receptor-mediated cytotoxicity into human ribonucleases by steric blockade of inhibitor interaction.
Suzuki M; Saxena SK; Boix E; Prill RJ; Vasandani VM; Ladner JE; Sung C; Youle RJ
Nat Biotechnol; 1999 Mar; 17(3):265-70. PubMed ID: 10096294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
